Wall Street brokerages expect Vascular Biogenics Ltd (NASDAQ:VBLT) to report $240,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Vascular Biogenics’ earnings, with the highest sales estimate coming in at $280,000.00 and the lowest estimate coming in at $200,000.00. Vascular Biogenics posted sales of $100,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 140%. The company is scheduled to issue its next earnings results before the market opens on Thursday, November 14th.
On average, analysts expect that Vascular Biogenics will report full-year sales of $810,000.00 for the current fiscal year, with estimates ranging from $700,000.00 to $920,000.00. For the next financial year, analysts anticipate that the firm will report sales of $870,000.00, with estimates ranging from $600,000.00 to $1.13 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Vascular Biogenics.
Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.25 million. Vascular Biogenics had a negative net margin of 3,021.20% and a negative return on equity of 35.35%.
Shares of VBLT opened at $1.26 on Thursday. The stock has a market capitalization of $44.85 million, a PE ratio of -2.03 and a beta of -0.29. Vascular Biogenics has a 1 year low of $0.60 and a 1 year high of $1.90. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.45 and a current ratio of 6.45. The company’s 50-day simple moving average is $1.27 and its 200-day simple moving average is $1.26.
Several hedge funds have recently added to or reduced their stakes in the stock. Athena Capital Advisors LLC increased its stake in shares of Vascular Biogenics by 216.7% in the 2nd quarter. Athena Capital Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 23,950 shares during the period. Morgan Stanley increased its stake in shares of Vascular Biogenics by 6.5% in the 2nd quarter. Morgan Stanley now owns 295,012 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 17,900 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Vascular Biogenics by 66.7% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 37,500 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 15,000 shares during the period. Hedge funds and other institutional investors own 5.38% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Article: What is diluted earnings per share (Diluted EPS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.